Patient-Oriented Outcome Assessment After Temporal Lobectomy for Refractory Epilepsy
Neurol 53:687-694, 662, Gilliam,F.,et al, 1999

The Contribution of Magnetic Resonance Imaging to the Diagnosis of Multiple Sclerosis
Neurol 53:448-456, Fazekas,F.,et al, 1999

Optic Neuritis as Onset Manifestations of Multiple Sclerosis
Neurol 53:473-478, Sorensen,T.L.,et al, 1999

Rehabilitation of Persons With Traumatic Brain Injury
JAMA 282:974-983,989, NIH Consensus Development Panel on Rehab with TBI, 1999

Multiple Sclerosis That is Progressive From the Time of Onset, Clinical Characteristics and Progression of Disability
Arch Neurol 56:1138-1142, Andersson,P.B.,et al, 1999

The Clinical Course of Neuromyelitis Optica (Devic's Syndrome)
Neurol 53:1107-1114, Wingerchuk,D.M.,et al, 1999

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999

Treatment Recommendations for Interferon-B in Multiple Sclerosis
JNNP 67:561-566, Polman,C.H.,et al, 1999

General Neurologist and Subspecialist Care for Multiple Sclerosis, Patients' Perceptions
Neurol 53:1190-1197, Vickrey,B.G.,et al, 1999

Fibromyalgia Syndrome a Decade Later
Arch Int Med 159:777-785, Goldenberg,D.L., 1999

Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999

Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999

Interferon-alpha 2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis
Neurol 52:1049-1056, Myhr,K.M.,et al, 1999

Quantitative MRI in CADASIL, Correlation with Disability and Cognitive Performance
Neurol 52:1361-1367, Dichgans,M.,et al, 1999

Brain Structure and Neurocognitive and Behavioural Function in Adolescents Who Were Born Very Preterm
Lancet 353:1653-1657, Stewart,A.L.,et al, 1999

Relevance of Hypointense Lesions on Fast Fluid-Attenuated Inversion Recovery MR Images as a Marker of Disease Severity in Cases of Multiple Sclerosis
AJNR 20:813-820, Rovaris,M.,et al, 1999

The Relationship of MS to Physical Trauma and Psychological Stress, Report of the Therapeutics and Technology Assessment Subcommittee of the AAN
Neurol 52:1737-1745, Goodin,D.S.,et al, 1999

Trigeminal Neuralgia Triggered by Auditory Stimuli in Multiple Sclerosis
Arch Neurol 56:731-733, Hartmann,M.,et al, 1999

Ibuprofen Treatment Versus Gradual Introduction of Interferon B-1b in patients with MS
Neurol 52:1893-1895, Rice,G.P.A.,et al, 1999

Cavernous Haemangioma Mimicking Multiple Sclerosis
BMJ 318:1604-1605, Cader,M.Z.&Winer,J.B., 1999

Cerebrospinal Fluid Findings in CADASIL
Neurol 53:233, Dichgans,M.,et al, 1999

Lamotrigine Adjunctive Therapy in painful Phenomena in MS:Preliminary Observations
Neurol 53:433, Cianchetti,C.,et al, 1999

Encephalitis after Hepatitis B Vaccination, Recurrent Disseminated Encephalitis or MS?
Neurol 53:396-401, Tourbah,A.,et al, 1999

Multiple Sclerosis,Therapeutic Update
Arch Neurol 56:277-280, Tselis,A.C.&Lisak,R.P., 1999

Neuropsychological Status in Multiple Sclerosis after Treatment with Glatiramer
Arch Neurol 56:319-324, Weinstein,A.,et al, 1999

Quantitative MRI in Patients with Clinically Isolated Syndromes Suggestive of Demyelination
Neurol 52:599-606, Sailer,M.,et al, 1999

Utilization of Unconventional Treatments by Persons with MS:Is It Alternative or Complementary?
Neurol 52:626-629, Schwartz,C.E.,et al, 1999

Multiple Sclerosis Associated with Uveitis in Two Large Clinic-Based Series
Neurol 52:179-181, Biousse,V.,et al, 1999

Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999

Magnetization Transfer Imaging of Patients with Definite MS and Negative Conventional MRI
Neurol 52:845-848, Filippi,M.,et al, 1999

Primary and Transitional Progressive MS,A Clinical and MRI Cross-Sectional Study
Neurol 52:839-845, Stevenson,V.L.,et al, 1999

Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis,Relation to Inflammatory Activity
Arch Neurol 56:345-351, van Walderveen,M.A.A.,et al, 1999

TI-201 SPECT in Pseudotumoral Multiple Sclerosis
Clin Nucl Med 24:186-188, Obach,V.,et al, 1999

Leukoencephalopathy and Raised Brain Lactate from Heroin Vapor Inhalation ("Chasing the Dragon")
Neurol 53:589-1048, Kriegstein,A.R., et al, 1999

Prediction of Stroke Outcome with Echoplanar Perfusion-and Diffusion-Weighted MRI
Neurol 51:418-426, Barber,P.A.,et al, 1998

MR Differential Diagnosis of Normal-Pressure Hydrocephalus and Alzheimer Disease:Significance of Perihippocampal Fissures
AJNR 19:813-819, Holodny,A.I.,et al, 1998

CSF Spaces in Idiopathic Normal Pressure Hydrocephalus:Morphology and Volumetry
AJNR 19:1277-1284, 12851998., Kitagaki,H.,et al, 1998

Magnetization Transfer Changes in Normal Appearing White Matter Precede Appear of Enhancing Lesions in Pts with MS
Ann Neurol 43:809-814, Filippi,M.,et al, 1998

Cerebellum in Attention-Deficit Hyperactivity Disorder
Neurol 50:1087-1093, Berquin,P.C.,et al, 1998

Clinicopath Conf
Demyelinating Process Consistent with Multiple Sclerosis, Case 26-1998, NEJM 339:542-549998., , 1998

The Predictive Value of CSF Ologoclonal Banding for MS 5 Years After Optic Neuritis
Neurol 51:885-887, Cole,S.R.,et al, 1998

The Phenotypic Spectrum of CADASIL:Clinical Findings in 102 Cases,
Ann Neurol 44:731-739,715, Dichgans,M.,et al, 1998

Surgical Treatment of Epilepsy in Tuberous Sclerosis,Strategies and Results in 18 Patients
Neurol 51:1263-1269, Guerreiro,M.M.,et al, 1998

Devic's Neuromyelitis Optica:A Prospective Study of Seven Patients Treated with Prednisone and Azathioprine
Neurol 51:1219-1220, Mandler,R.N.,et al, 1998

Interferon B Therapy for Multiple Sclerosis
Lancet 352:1486-1487, Goodkin,D.E., 1998

Interferons in the Treatment of Multiple Sclerosis,Do They Prevent the Progression of the Disease?
Arch Neurol 55:1578-1580,1583, Rice,G.&Ebers,G, 1998

Interferons Should be Used to Treat Most Patients with MS
Arch Neurol 55:1581-1583, Herndon,R.M.&Jacobs,L, 1998

Randomised Double-Blind Placebo-Controlled Study of Interferon B-1a in Relapsing/Remitting Multiple Sclerosis
Lancet 352:1498-1504,1486, PRISMS, 1998

An Open-Label Trial of Gabapentin Treatment of Paroxysmal Symptoms in Multiple Sclerosis Patients
Neurol 51:609-611, Solaro,C.,et al, 1998

Gabapentin Relieves Trigeminal Neuralgia in Multiple Sclerosis Patients
Neurol 51:611-614, Khan,O.A., 1998